Reviewing Axsome Therapeutics Inc. (AXSM)’s and Corvus Pharmaceuticals Inc. (NASDAQ:CRVS)’s results

We will be contrasting the differences between Axsome Therapeutics Inc. (NASDAQ:AXSM) and Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) as far as institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Axsome Therapeutics Inc. N/A 0.00 36.80M -1.15 0.00
Corvus Pharmaceuticals Inc. N/A 0.00 44.28M -1.75 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Axsome Therapeutics Inc. and Corvus Pharmaceuticals Inc.


Table 2 has Axsome Therapeutics Inc. and Corvus Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Axsome Therapeutics Inc. 0.00% 0% 0%
Corvus Pharmaceuticals Inc. 0.00% -38.7% -35.7%


Axsome Therapeutics Inc.’s Current Ratio is 5.7 while its Quick Ratio is 5.7. On the competitive side is, Corvus Pharmaceuticals Inc. which has a 12.4 Current Ratio and a 12.4 Quick Ratio. Corvus Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Axsome Therapeutics Inc.

Analyst Recommendations

Axsome Therapeutics Inc. and Corvus Pharmaceuticals Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Axsome Therapeutics Inc. 0 0 2 3.00
Corvus Pharmaceuticals Inc. 0 0 0 0.00

Axsome Therapeutics Inc. has a 9.51% upside potential and a consensus price target of $25.

Institutional and Insider Ownership

Roughly 19.9% of Axsome Therapeutics Inc. shares are owned by institutional investors while 86% of Corvus Pharmaceuticals Inc. are owned by institutional investors. About 2.1% of Axsome Therapeutics Inc.’s share are owned by insiders. Comparatively, Corvus Pharmaceuticals Inc. has 0.9% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Axsome Therapeutics Inc. 17.11% 60.73% 151.64% 494.32% 557.14% 715.6%
Corvus Pharmaceuticals Inc. 9.63% 14.43% 3.98% -43.87% -54.83% 20.98%

For the past year Axsome Therapeutics Inc. was more bullish than Corvus Pharmaceuticals Inc.


Axsome Therapeutics Inc. beats Corvus Pharmaceuticals Inc. on 6 of the 7 factors.

Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the management of central nervous system (CNS) disorders. The companyÂ’s product candidates include AXS-05 that is in Phase III trial for the treatment of treatment resistant depression and AlzheimerÂ’s disease agitation; and AXS-02, which is in Phase III trial to treat complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing AXS-06, a preclinical product candidate for CNS disorders, including chronic pain. The company was founded in 2012 and is based in New York, New York.

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint. The company is also developing an anti-CD73 monoclonal antibody that inhibits the production of adenosine; an antagonist of the adenosine A2B receptor; and small molecule covalent inhibitors of interleukin-2 inducible kinase. Corvus Pharmaceuticals, Inc. was founded in 2014 and is based in Burlingame, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.